Acquired Immunodeficiency Syndrome (AIDS), 1-23 Aspergillosis In, 16-18
Index Acquired immunodeficiency syndrome enzyme activities and, 336-339 (AIDS), 1-23 fatty acid synthesis and, 334-336 aspergillosis in, 16-18 ergosterol synthesis inhibition by, candidiasis in, 6-11 316-320 coccidioidomycosis in, 15--16 membrane and cell functions and 14 cryptococcosis in, 11-15 alpha-methylsterol effects, 326- histoplasmosis in, 15--16 329 host resistance in, 6 membrane lipid interactions of, 339- immunofluorescent staining for tissue 341 section in, 4-5 selective toxicity of, 325--326 Malassezia furfur in, 21 Antigen nocardiosis in, 18-20 of Aspergillus fumigatus, 198-199 pathologic diagnosis in, 3-4 advancing line immunoelectrophoresis Actinomyces, monoclonal antibodies in, for, 176 196 of Blastomyces dermatitidis, 199 Adriamycin, 133 of Candida albicans, 199-200 Adrucil, 133 of Coccidioides immitis, 200 Aerosporin, 114 of Cryptococcus neoformans, 200--201 Alkeran, 133 crossed immunoelectrophoresis for, Amantadine HCI, 140 174-175 Amikacin sulfate, 107 crossed-tandon immunoelectrophoresis Amikin,107 for, 176-178 Aminoglycoside, 106f, 107 of dermatophyte, 201 Aminosalicylic acid, 123-124 of Histoplasma capsulatum, 201-202 Amphotericin B, 127 methods for determining chemical na- Ancobon, 127-128 ture of, 180 Antifungal agents, systemic, 126f, 127- monitoring isolation of, 176-181 129 rocket immunoelectrophoresis for, 176 Antifungal azole derivatives, 313-351 of Sporothrix schenckii, 202 cytochrome P-450 interation with, of zygomycetes, 202 320--323 Antineoplastic agents, 131-135, 132f,134t ergosterol depletion effects
[Show full text]